About Professor Gerald Fogarty
BSc MBBS PhD FRANZCR FRO OAM KSG
Prof Gerald Fogarty is a radiation oncologist with a special interest in the radiation treatment of skin conditions.
Medical training
He was in the first year of the combined science-medicine degree at the University of NSW graduating in 1983 with honours. He completed his specialist training in radiotherapy at Peter MacCallum Cancer Centre in Melbourne, Australia’s largest cancer centre, colloquially known as the Peter Mac. He won the Varian prize for Peter Mac for the first time in 25 years in 2000, a prize given to the best registrar presentation at the annual scientific meeting of the Royal College. He completed a skin fellowship at Peter Mac. He was the Director of the Radiotherapy services at the Mater and St Vincent’s Hospitals, Sydney until 2021. He now works in Sydney for Icon Cancer Centres, an Australian-based international company.
Awards, Achievement and Contributions
Professor Gerald Fogarty was awarded an OAM for services to medical research in 2025. He was also made a Knight of the Order of Saint Gregory the Great by Pope Leo XIV in 2025 for services to Catholic Tertiary Education. He has over 200 publications and conference presentations. He has a H-index or 32 (Googe scholar accessed January 2026). He is a Professor at Monash University in Melbourne, and Universities of Notre Dame Australia and University of Technology, Sydney.
He authored the radiotherapy section of the 2019 Management of Keratinocyte Guidelines for Cancer Australia. He has spearheaded to use of modern radiotherapy techniques such as Intensity Modulated Radiotherapy (IMRT), Volumetric Modulated Arc Therapy (VMAT) and Stereotactic Radiosurgery (SRS) and therapy (SBRT or SABR) in skin. Following 35 years on staff and 13 years of service as the Master of Warrane College, an affiliated residential College at UNSW, he now holds the Emeritus Master role.
Career Goal
His career goal is the establishing of the evidence base for radiation therapies in skin, principally through prospective trials to ensure optimum patient and national health outcomes.
